Our Pipeline

We challenge ourselves to rethink the way medicines are developed,
and are investing now to bring more value to patients in the future.

We strive for constant innovation and we are putting our passion and expertise to work in new areas ophthalmology, gastroenterology, and hematology.

SB8

Biosimilar candidate

Molecule	Bevacizumab
Reference Biologic	Avastin®[i]
Therapeutic Area	Oncology

Preclinical | Phase I | Phase III | Filing | Approval

Learn more about the clinical trial

SB11

Biosimilar candidate

Molecule	Ranibizumab
Reference Biologic	Lucentis®[ii]
Therapeutic Area	Ophthalmology

Preclinical | Phase I | Phase III | Filing | Approval

Learn more about the clinical trial

SB12

Biosimilar candidate

Molecule	Eculizumab
Reference Biologic	Soliris® [iii]
Therapeutic Area	Hematology

Learn more about the clinical trial

SB15

Biosimilar candidate

Molecule	Aflibercept
Reference Biologic	Eylea® [iv]
Therapeutic Area	Ophthalmology

SB26

Novel biologic

Molecule	Ulinastatin-Fc Fusion Protein
Therapeutic Area	Gastroenterology

Learn more about the clinical trial

⋆ Pipeline la

i Avastin® is a registered trademark of Genentech

ii Lucentis® is a registered trademark of Genentech

iii Soliris® is a registered trademark of Alexion

iv Eylea® is a registered trademark of Regeneron

Our Products

Our Partners

Copyright © 2019 Samsung Bioepis. All